Skip to main content
. 2011 Sep 21;118(19):5119–5125. doi: 10.1182/blood-2011-07-362475

Table 2.

Response rates for entire cohort (N = 38) and per protocol response evaluable patients (n = 36)

Type of response Patients, n Entire cohort, % Response evaluable, %
CR 1 2.6% 2.8%
PR 6 15.7% 16.6%
SD > 6 months 5 13.2% 13.9%
ORR (CR + PR) 7 18.4% 19.4%
Cytostatic ORR (CR + PR + SD ≥ 6 mo) 12 31.6% 33.3%